Stroke in Biological Technology

D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients

... III clinical trial of DP-b99 in acute ischemic stroke patients has been approved by the US Food and ... enroll 770 moderate to severely affected ischemic stroke patients worldwide, with first patients expected ... an array of brain damaging processes occurring in stroke patients and emerged from D-Pharm's proprietary ...

deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes

... on 4q25 correlates to both an increased risk of stroke and up to twice the average risk of AF(3), a ... factor provides a new means of identifying stroke patients who could most benefit from outpatient ... that AF is a much greater cause of stroke than previously recognized," Circulation ...

Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards

... said, "Moleac has identified a need gap in the stroke recovery process and has adopted an innovative ... our efforts on making NeuroAid available to stroke sufferers around the world. NeuroAid is the first medicine to support stroke recovery, and this is a huge unmet need ...

AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer

... to increase awareness of the leading cause of stroke and heart disease, and help Americans fight ... 800,000 Americans each year.(2) Together, CHD and stroke kill more Americans every year than all cancers ... Accessed January 16, 2009 (3) Heart Disease and stroke Statistics: 2009 Update. American Heart ...

Concentric Medical Closes on $15 Million Financing

... leader in devices for clot removal in ischemic stroke patients, today announced that it has completed a ... extends the company's lead in the acute ischemic stroke market. In September 2008, Concentric ... Retrieval System is available in over 250 leading stroke centers around the world, and has been the ...

PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies

... with Safe Implementation of Treatments in stroke (SITS) International, the world's largest network ... to the treatment of patients suffering from acute stroke and to the conduct of Phase II - IV ... of clinical programs focused on advancing new stroke treatments," according to Mark A. Goldberg, M.D., ...

deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke

... is feasible on all patients who have suffered stroke or transient ischemic attack (TIA). deCODE's ... means that AF causes an even larger proportion of stroke than previously believed, making tools like ... in preventing AF. Testing all of their stroke and TIA patients with deCODE AF(TM), doctors can ...

ThromboGenics N.V.: Business Update

... when administered intravenously to acute stroke patients. The overall results of the study were ... by Dr. Vincent Thijs on September 27 at the World stroke Congress in Vienna. The MITI IV (Microplasmin In Treatment of Ischemic stroke - IntraVenous) trial was a Phase II, multicentre, ...

Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation

... novel oral Factor Xa inhibitor anticoagulant, for stroke prevention in patients with atrial fibrillation ... and subsequently blocks an artery in the brain, a stroke results. According to the joint ACC/AHA/ESC ... a two- to seven-fold increased risk of stroke and also have an increased risk of death and ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... specific numeric data. Screenings include: -- stroke Screening -- Multiple ultrasound images of the ... Artery Disease is a leading cause of these clots. stroke is the leading cause of serious long-term ... carotid arteries is the single best predictor of stroke and heart disease. -- Abdominal Aortic Aneurysm ...

Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System

... associated with severe oxygen deprivation such as stroke or cardiac arrest. Therapeutic hypothermia ... be administered within three hours of onset, many stroke patients continue to suffer advanced neurologic ... they have received tPA. More importantly, most stroke victims do not arrive at the hospital in time ...

Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat

... Every five minutes, someone in the U.S. has a stroke caused by AF. stroke is our #3 killer and the #1 cause of permanent ... Program for Health and Longevity, had a near stroke from AF. "Over five million Americans now ...

Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery

... a significant decrease in the rate of stroke for patients treated with PCI as compared to CABG. "The significant difference in the stroke rate between the PCI and the CABG groups is an ... groups, with a combined rate of all-cause death, stroke and MI of 7.6 percent for PCI and 7.7 percent for ...

Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care

... InTouch Health to facilitate the advancement of stroke care in the U.S. Concentric Medical and InTouch ... patients the broadest range of options in acute stroke intervention. Concentric Medical provides Merci ... patients that present to the hospital with acute stroke symptoms. Maria Sainz, President and CEO of ...

Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines

... of those at even higher risk for heart attack and stroke who would benefit from proven therapeutic and ... epidemiological studies of Lp-PLA2 and stroke risk, and states that "determining patients at high risk for stroke may be challenging because total and LDL ...

Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke

... Registry reveals that 70% of deaths in the stable stroke population were due to a cardiovascular event ... from the REACH Registry presented at the European stroke Congress, highlight that among those who die after a stroke the vast majority (73%) will die from nonstroke ...

ThromboGenics N.V. - Business Update

... flow efficiently for a longer period after the stroke event, and with potentially fewer side-effects ... doses when administered intravenously to acute stroke patients between four and twelve hours after the ... when administered intravenously to acute stroke patients. Once these data from the study have ...

ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase

... from the first cohort of our TUCSON stroke study and believe that SonoLysis has the ... several other vascular disorders beyond ischemic stroke including peripheral artery disease, deep ... development efforts are focused on therapies for stroke and other vascular disorders using its ...

ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke

... when administered intravenously to acute stroke patients between four and twelve hours after the ... MITI IV (Microplasmin in Treatment of Ischemic stroke - IntraVenous) is a Phase II, multicentre, ... efficiently within an extended period after a stroke event and has potentially fewer side-effects than ...

Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems

... associated with severe oxygen deprivation such as stroke or cardiac arrest. Therapeutic hypothermia ... be administered within three hours of onset, many stroke patients continue to suffer advanced neurologic ... they have received tPA. More importantly, most stroke victims do not arrive at the hospital in time ...

Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over

... reducing blood pressure in the under-80s reduces stroke and cardiovascular events. However, ... significant reductions in overall mortality and stroke in those receiving treatment. The final results ... 1. About high blood pressure and stroke - stroke is the third most common cause of death in ...

Moleac Launches NeuroAid10(TM) in the United States

... NeuroAid(TM) on recovery several months after a stroke has triggered large interest in the neurology ... starting within 48 hours of a stroke. "The CHIMES stroke Study is ground-breaking for the medical industry as the largest clinical trial on stroke recovery and the first time any TCM product has ...

New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)

... of a composite endpoint of cardiovascular death, stroke and myocardial infarct (MI) and the results are ... approved to reduce the risk of heart attack and stroke across the entire spectrum of ACS. Plavix(R) is ... in patients with a history of recent MI, recent stroke or established peripheral arterial disease ....

D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99

... DP-b99 is a unique drug protecting brain cells in stroke patients, discovered and developed by D-Pharm. ... a Phase IIb trial for DP-b99 in 150 ischemic stroke patients. Results from this study will ... and to recruit about 750 moderately severe acute stroke patients in North America, Europe and Asia. ...

Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration

... events such as non-fatal heart attack, non-fatal stroke and cardiovascular death in 13,608 patients. In ... endpoint of non-fatal heart attack, non-fatal stroke or cardiovascular death (p -- 52 percent ... American Heart Association. Heart Disease and stroke Statistics - 2006 Update. Dallas, TX. ...

FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)

... against a future heart attack or stroke for patients with ACS (UA, NSTEMI, STEMI) and ... rate of a combined end point of new ischemic stroke (fatal or not), new MI (fatal or not), and other ... end point of cardiovascular death, MI, or stroke as well as the rate of a combined end point ...

ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402

... and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as ... conditions, such as deep vein thrombosis and stroke secondary to atrial fibrillation. We are looking ... as an important option for the treatment of VTE. stroke Prevention in Atrial Fibrillation (AF) Atrial ...

Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models

... that investigators of the National Institute of Neurological Disorders and stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of ... About the National Institute of Neurological Disorders and stroke (NINDS), (NIH): NINDS ( www.ninds.nih.gov ) is a component of the ...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... risk of the combined endpoint of cardiovascular death, heart attack, or stroke by 19 percent (9.9 percent versus 12.1 percent), with an increased risk of ... 5) Ibid 6) American Heart Association. Heart Disease and stroke Statistics - 2008 Update. Dallas, TX. American Heart Association. (Pg. ....

Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)

... The primary endpoint at two years is survival while remaining free from stroke and the need for reoperation for pump repair or replacement. Secondary ... performance and the primary patient outcome of two-year survival free from stroke and reoperation for device replacement. The data also showed that key ...

ThromboGenics Announces Business Update and 2008 Full Year Results

... KULeuven, presented the results from this 40 patient study at the World stroke Congress in Vienna, Austria. It remains ThromboGenics' intention that it ... move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. TB-402 - Anti-coagulant: Begins ...

Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009

... innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative ... pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development ...

Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)

... deCODEme Cardio(TM), which detects genetic risk factors for heart attack, stroke and atrial fibrillation, peripheral artery disease (PAD), and several ... the risk of heart attack, intracranical and abdominal aortic aneurysm, stroke and atrial fibrillation, peripheral arterial disease (PAD) and venous ...

Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings

... innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative ... pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional ...

Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009

... that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the ... of XERECEPT(R) by Celtic, the development of Viprinex for acute ischemic stroke by NTI, delays or other problems with our clinical trials, the outcome of ...

Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units

... co-sponsored study is the Intravascular Cooling in the Treatment of stroke -- Longer tPA window (ICTuS-L) study, which is a prospective, randomized, ... study, sponsored by the National Institute of Neurological Disorders and stroke (NINDS). The study is evaluating the safety and feasibility of InnerCool's ...

Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting

... (11dhTxB2) levels affirmed as independent predictor of heart attack and stroke risk in aspirin-treated patients DENVER, Nov. 5 /PRNewswire-FirstCall/ ... thromboxane B2 (11dhTxB2) indicate an increased risk of heart attack, stroke and cardiac death. The AspirinWorks Test by Corgenix is the only ...

NovaVision CEO Named Presenter at the AdvaMed 2008 Conference

... the millions of underserved people living with impaired sight caused by a stroke or traumatic brain injury (TBI). Using the science of neuroplasticity -- ... show improved vision following therapy, regardless of how long ago their stroke or TBI occurred. About NovaVision, Inc. NovaVision, Inc., ...

Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification

... re-warming, and potential additional applications including acute ischemic stroke and myocardial infarction (heart attack). The CE Mark will allow the ... technology include endovascular cooling for cardiac arrest, acute ischemic stroke and myocardial infarction (heart attack). InnerCool's CoolBlue(TM) ...

Neurobiological Technologies' CEO to Retire on December 31, 2008

... to where we have a Phase 3 program in a highly underserved acute ischemic stroke market and his contributions with XERECEPT(R) and Memantine to our ... that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the ...